• Phare
  • Validé par KD/KO

Anticorps Monoclonal anti-Cyclin B2

Cyclin B2 Monoclonal Antibody for WB, IHC, IF/ICC, IF-P, Indirect ELISA

Hôte / Isotype

Mouse / IgG2a

Réactivité testée

Humain, souris

Applications

WB, IHC, IF/ICC, IF-P, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

2G8B7

N° de cat : 67726-1-PBS

Synonymes

CCNB2, G2/mitotic-specific cyclin-B2, G2/mitotic specific cyclin B2, Cyclin B, 2G8B7



Informations sur le produit

67726-1-PBS cible Cyclin B2 dans les applications de WB, IHC, IF/ICC, IF-P, Indirect ELISA et montre une réactivité avec des échantillons Humain, souris

Réactivité Humain, souris
Hôte / Isotype Mouse / IgG2a
Clonalité Monoclonal
Type Anticorps
Immunogène Cyclin B2 Protéine recombinante Ag16329
Nom complet cyclin B2
Masse moléculaire calculée 398 aa, 45 kDa
Poids moléculaire observé45 kDa
Numéro d’acquisition GenBankBC105086
Symbole du gène Cyclin B2
Identification du gène (NCBI) 9133
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Cyclin B2 (CCNB2) is a member of cyclin family proteins, which regulate the activities of cyclin dependent kinases (CDKs) and different cyclins function spatially and temporally in specific phases of the cell cycle. Cyclin B2 serves a key role in progression of G2/M transition. Cyclin B2 has been found to be up-regulated in a variety of human cancers, such as adrenocortical carcinoma, breast carcinoma, colorectal adenocarcinoma, pituitary adenoma and gastric cancer. The aberrant expression of Cyclin B2 deregulates spindle checkpoints in the cell cycle and results in chromosomal instability (CIN), one of the signature phenotypes of most cancers. Moreover, serum circulating Cyclin B2 mRNA expression has been found increased in cancer patients and associated with cancer stage and metastasis status.

{{ptg:RelatedPrimaryAntibodies}}